Evan Y. Yu

Evan Yu is a nationally recognized academic prostate cancer oncologist at Fred Hutchinson Cancer Center and the University of Washington in Seattle, where he has built one of the most active prostate cancer clinical trial programs in the Pacific Northwest. His career has focused on the clinical development of novel agents for castration-resistant prostate cancer, with particular contributions to the evaluation of cabazitaxel, radium-223, and hormonal agents in diverse patient populations including those with variant histologies and DNA repair deficiencies. Yu was a key investigator in studies of cabazitaxel and played an important role in the comparative effectiveness studies that helped define its optimal positioning in the CRPC treatment sequence. He was a principal investigator in studies of radium-223 dichloride, including research on its mechanism of action in bone-dominant CRPC and on combination strategies with novel hormonal agents. His work on bone-metastatic CRPC has contributed to understanding radium-223's effects on the bone microenvironment and the potential for synergy with agents targeting the AR axis or the tumor immune microenvironment. As a clinical investigator and SWOG cooperative group member, Yu has contributed to multi-center trials examining novel combinations in CRPC, including studies of PARP inhibitors combined with novel hormonal agents in DNA repair-deficient disease. He has also contributed to research on neuroendocrine differentiation and treatment-emergent neuroendocrine prostate cancer (NEPC) — a highly aggressive CRPC variant — including understanding its molecular drivers and developing clinical approaches to its management. His leadership in the Pacific Northwest makes him a key figure in the regional and national GU oncology community.

Evan Yu 是弗雷德哈钦森癌症中心和华盛顿大学的知名前列腺癌肿瘤学家，在太平洋西北地区建立了最活跃的前列腺癌临床试验项目之一。他的研究集中于去势抵抗性前列腺癌新型药物的临床开发，特别是卡巴他赛、镭-223 以及DNA修复缺陷和神经内分泌分化患者的治疗。 Yu 在镭-223 和卡巴他赛研究中担任主要研究者，为理解这些药物在骨转移性 CRPC 中的最佳定位及与其他药物的联合策略做出了重要贡献。